Insights On Upstream Manufacturing

  1. Comparing Serum-free To Serum-Supplemented Media 6/9/2025

    Reducing serum in vaccine manufacturing is a key consideration for lowering costs and improving supply security. We compare performance in serum-free versus serum-supplemented media.

  2. A Temperature-Stable Replacement For Animal Trypsin In Cell Dissociation Applications 6/9/2025

    Improve cell dissociation with a gentle, recombinant enzyme. This temperature-stable protease shows dissociation kinetics similar to porcine trypsin but with lower cell toxicity and greater overall purity.

  3. CTS DynaCellect Fluidics Demonstration 6/9/2025

    Streamline and customize your cell processing workflow with automated, precise control over fluid movement and transfer parameters.

  4. Advances In Custom Medium Development The Multi-Omics Difference 6/9/2025

    Spent media analysis continues to be an essential part of many media development workflows. Newer techniques, however, using state-of-the-art analytical technology, are becoming more popular.

  5. Uninstalling CTS Dynacellect Bead Removal Kit 6/9/2025

    A detailed walkthrough on how to uninstall the Gibco CTS DynaCellect Bead Removal Kit when the bead removal protocol or the Gibco CTS DynaCellect magnetic separation system is completed.

  6. Advances In Microbial Fermentation Knowledge Culture 6/9/2025

    Presented by three experts, this session examines real-world examples of how different approaches to media formulation and process conditions can influence outcomes.

  7. Exploring The Challenges Of Cell Dissociation In Vaccine Manufacturing 6/9/2025

    Vaccine manufacturing relies on efficient cell dissociation methods. Explore the challenges of traditional approaches like trypsin and the benefits of animal origin-free alternatives for improved workflows.

  8. Optimize Your Advanced Therapy Manufacturing Process Before You Automate 6/5/2025

    Dive into specific unit operations and case studies that demonstrate how implementing phase appropriate tools can have substantive direct business impacts to cost and development timelines.

  9. Simplify CAR-T Cell Manufacturing With LNP-Mediated Delivery 6/3/2025

    Streamline CAR-T cell manufacturing with lipid nanoparticles delivering base editors to create fratricide-resistant, CD45-edited CAR45 T cells, which enables scalable, precise, and potent therapies for blood cancers.

  10. Versatile Lipid Nanoparticle Platform For Efficient Gene Editing 6/3/2025

    Lipid nanoparticles enable efficient gene editing in hard-to-transfect cells like T-cells and blood stem cells, which offers scalable, clinically relevant methods for developing advanced therapies for cancer and rare diseases.